Literature DB >> 1473289

Bradycardia during reversible hypovolaemic shock: associated neural reflex mechanisms and clinical implications.

N H Secher1, J Jacobsen, D B Friedman, S Matzen.   

Abstract

1. Heart rate response to reversible central hypovolaemia can be divided into three stages. In the first stage (corresponding to a reduction of the blood volume by approximately 15%) a modest increase in heart rate (< 100 beats/min) and total peripheral resistance compensate for the blood loss, and a near normal arterial blood pressure prevails (preshock). During the second stage, a reduction of the central blood volume by approximately 30% results in a decrease in heart rate, total peripheral resistance and blood pressure due to activation of unmyelinated vagal afferents (C-fibres) from the left ventricle. In the third stage, blood pressure falls further as haemorrhage continues and tachycardia (> 120 beats/min) is manifest. This stage may proceed into irreversible shock with death from cardiac arrest probably related to the formation of free oxygen radicals. 2. Recognition of the vasodepressor-cardioinhibitory reaction to a reduced circulating blood volume is important and suggests the need for immediate treatment with volume expansion in critically ill patients.

Entities:  

Mesh:

Year:  1992        PMID: 1473289     DOI: 10.1111/j.1440-1681.1992.tb00411.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  13 in total

1.  Impaired blood pressure recovery to hemorrhage in obese Zucker rats with orthopedic trauma.

Authors:  Lusha Xiang; Silu Lu; William Fuller; Arun Aneja; George V Russell; Louis B Jones; Robert Hester
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-10-14       Impact factor: 4.733

2.  Spectral analysis of finger photoplethysmographic waveform variability in a model of mild to moderate haemorrhage.

Authors:  Paul M Middleton; Gregory S H Chan; Emma O'Lone; Elizabeth Steel; Rebecca Carroll; Branko G Celler; Nigel H Lovell
Journal:  J Clin Monit Comput       Date:  2008-10-11       Impact factor: 2.502

3.  The Effects of Acute Blood Loss for Diagnostic Bloodwork and Fluid Replacement in Clinically Ill Mice.

Authors:  James O Marx; JanLee A Jensen; Stacie Seelye; Raquel M Walton; F Claire Hankenson
Journal:  Comp Med       Date:  2015-06       Impact factor: 0.982

Review 4.  Physiological Mechanisms of Hypertension and Cardiovascular Disease in End-Stage Kidney Disease.

Authors:  John S Clemmer; Tariq Shafi; Yoshitsugu Obi
Journal:  Curr Hypertens Rep       Date:  2022-06-16       Impact factor: 4.592

5.  Quantitative fluorescence angiography detects dynamic changes in gastric perfusion.

Authors:  Jens Osterkamp; Rune Strandby; Nikolaj Nerup; Morten Svendsen; Lars Svendsen; Michael Achiam
Journal:  Surg Endosc       Date:  2020-11-30       Impact factor: 4.584

6.  Hemodynamic and autonomic response to acute hemorrhage in streptozotocin-induced diabetic rats.

Authors:  Aiji Boku; Mitsutaka Sugimura; Yoshinari Morimoto; Hiroshi Hanamoto; Hitoshi Niwa
Journal:  Cardiovasc Diabetol       Date:  2010-11-25       Impact factor: 9.951

7.  Protective role of selective nitric oxide synthase inhibitor for treatment of decompensated hemorrhagic shock in normotensive and hypertensive rats.

Authors:  Majid Khazaei; Babak Barmaki; Ali Nasimi
Journal:  Int J Prev Med       Date:  2012-01

Review 8.  Noninvasive continuous hemodynamic monitoring.

Authors:  Jasper Truijen; Johannes J van Lieshout; Wilbert A Wesselink; Berend E Westerhof
Journal:  J Clin Monit Comput       Date:  2012-06-14       Impact factor: 2.502

9.  Developmentally regulated effects of severe hemorrhage on cardiovascular homeostasis and the arterial baroreflex control of heart rate.

Authors:  Mohamed Samhan; Wei Qi; Francine G Smith
Journal:  Physiol Rep       Date:  2015-07

Review 10.  Seven Mathematical Models of Hemorrhagic Shock.

Authors:  Luciano Curcio; Laura D'Orsi; Andrea De Gaetano
Journal:  Comput Math Methods Med       Date:  2021-06-03       Impact factor: 2.238

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.